Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Theratechnologies Inc. (NASDAQ:THTX), a pharmaceutical company with a market capitalization of $17.74 billion, has announced its annual meeting of shareholders will be held on April 30, 2025. The notice, filed today with the Securities and Exchange Commission (SEC), includes the management proxy circular and form of proxy for the upcoming meeting. According to InvestingPro data, the company maintains a strong financial health score of GOOD, with liquid assets significantly exceeding short-term obligations.
The materials provided in the SEC filing, specifically Exhibit 99.1, detail the notice of the annual meeting, while Exhibit 99.2 contains the management proxy circular dated April 30, 2025. Additionally, Exhibit 99.3 includes the form of proxy that shareholders will use to cast their votes.
The announcement was made pursuant to the requirements of the Securities Exchange Act of 1934 and was signed by Jocelyn Lafond, General Counsel and Corporate Secretary of Theratechnologies Inc. The company, headquartered in Montreal, Quebec, specializes in pharmaceutical preparations and is incorporated under the laws of A8, with a fiscal year ending on November 30.
The filing does not disclose specific agenda items or proposals to be presented at the annual meeting, but such events typically include the election of board members, approval of financial statements, and other corporate governance matters.
Investors and interested parties can find the full text of the SEC filing, including the exhibits mentioned, for further details. The information is based on a press release statement filed with the SEC.
In other recent news, ON Semiconductor (NASDAQ:ON) has made significant headlines with its latest developments. The company recently decided to terminate its acquisition proposal for Allegro (WA:ALEP) MicroSystems, citing a lack of actionable path forward after Allegro’s board showed reluctance. This strategic pivot led ON Semiconductor to focus on its existing share repurchase program, aiming to enhance shareholder value. In parallel, ON Semiconductor has faced challenges with its fabrication facilities, impacting gross margins due to underutilization and costs related to new production capabilities.
Analysts have also adjusted their expectations for ON Semiconductor. Stifel has lowered its 12-month price target from $52 to $42, maintaining a Hold rating, due to macroeconomic concerns and specific challenges within the automotive sector. KeyBanc Capital Markets reduced its price target to $55 from $60, while maintaining an Overweight rating, reflecting weaker demand trends and ongoing inventory reductions by auto manufacturers. Additionally, ON Semiconductor is among the U.S. chip manufacturers potentially affected by China’s new tariff rules, which classify chips produced in U.S.-based plants as U.S. origin, subjecting them to high tariffs.
These developments come amid a broader context of investor crowding in various stocks, as noted by UBS, although ON Semiconductor was not specifically highlighted in their findings. Investors and analysts are closely monitoring ON Semiconductor’s strategic decisions and market conditions, as these factors play a crucial role in the company’s financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.